Simplifying HIV Treatment in the Presence of Drug Resistance; Preventing from the Start : Episode 7

Opinion

Video

June 7, 2024

HIV Drug Resistance Testing Practices and Patient Education

Author(s):

Paul E. Sax, MD,Shauna Applin, ARNP

Experts on HIV provide clinical insights on testing for drug resistance prior to treatment and approaching the topic of resistance with patients.

EP: 1.The Role of the Primary Care Provider/Advanced Practice Provider in HIV Management

EP: 2.Evolving Treatment Practices and Guidelines for HIV

EP: 3.Key Clinical Considerations in HIV Treatment Decisions

EP: 4.HIV Treatment: Discussing Adverse Events with Patients

EP: 5.Importance of Starting HIV Treatment Early

EP: 6.Treatment Resistance in HIV

EP: 7.HIV Drug Resistance Testing Practices and Patient Education

EP: 8.Managing Suboptimal Adherence to HIV Medications

EP: 9.HIV Treatment Clinical Experiences

EP: 10.Addressing Suboptimal Treatment Response in HIV

EP: 11.Current HIV Treatment Regimens

EP: 12.Rapid Treatment Initiation in HIV

EP: 13.Switching Therapies for Patients with HIV and History of Resistance

EP: 14.Resources Available for Patients with HIV Drug Resistance

EP: 15.Factors that Inform Treatment Selection in HIV

EP: 16.Switching Therapies in HIV

EP: 17.Restarting Therapy in Patients with HIV

EP: 18.Treatment Guidelines and Regimens for Managing Patients with HIV

EP: 19.Differences in Binding Affinity Between Integrase Inhibitors in HIV

EP: 20.Head-to-Head Comparisons on B/F/TAF Compared With Other HIV Regimens

EP: 21.Recent Studies on HIV Treatments and Patient-Reported Outcomes

EP: 22.HIV: Treating Patients with Viral Mutations

BIC = bictegravir

DRV = darunavir

DTG = dolutegravir

F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide

F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate

B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)

DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)

D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)

CAB = Cabotegravir

CAB + RPV = Cabotegravir + Rilpivirine

Video content above is prompted by the following question:

How has resistance in HIV treatment changed over the years?
1. FDA approvals have provided options for those with resistance.
How do you test for HIV drug resistance prior to treatment?
1. How do you monitor for development of resistance?
2. How you determine to stay on current treatment or switch therapies?
  1. long acting injectables vs oral treatments
  2. protection against resistance
What recommendations do you have for physicians and advanced practice providers in the community setting?

Related Videos

Steven Fein, MD | Credit: University of Michigan

Steven Fein, MD | Credit: University of Michigan

Steven Fein, MD | Credit: University of Michigan

Steven Fein, MD | Credit: University of Michigan

Steven Fein, MD | Credit: University of Michigan

Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine

Virginia Clark, MD | Credit: University of Florida Health

Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD

Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management | Image Credit: Emory University

Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.